Roche share price hasn’t exceeded the 20% return since the first swine flu symptoms were reported in Mexico in April 2009, a clear indication that Tamiflu is not the solution to the swine flu pandemic. Relenza, produced by GlaxoSmithKline, is also reporting the same ineffective results primarily over children under 12.

The recent deaths of healthy people in the US and UK suggests the virus is mutating. We can only hope that the new altered swine flu virus doesn’t transmit as easily.